Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) fell 4.6% on Thursday . The company traded as low as $10.00 and last traded at $10.06. 1,367,808 shares were traded during mid-day trading, an increase of 305% from the average session volume of 337,931 shares. The stock had previously closed at $10.54.
Silverback Therapeutics Stock Down 2.3%
The firm has a 50 day simple moving average of $10.53 and a two-hundred day simple moving average of $11.57. The stock has a market capitalization of $360.22 million, a P/E ratio of -4.13 and a beta of 0.60.
About Silverback Therapeutics
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Featured Stories
- Five stocks we like better than Silverback Therapeutics
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
